Your browser doesn't support javascript.
loading
Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein.
Masuda, Yusuke; Yamaguchi, Shinji; Suzuki, Chikako; Aburatani, Takahide; Nagano, Yuki; Miyauchi, Ryuki; Suzuki, Eiko; Yamamura, Naotoshi; Nagatomo, Kentaro; Ishihara, Hidetoshi; Okuno, Kazuaki; Nara, Futoshi; Matschiner, Gabriele; Hashimoto, Ryuji; Takahashi, Tohru; Nishizawa, Tomohiro.
Afiliación
  • Masuda Y; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Yamaguchi S; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Suzuki C; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Aburatani T; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Nagano Y; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Miyauchi R; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Suzuki E; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Yamamura N; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Nagatomo K; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Ishihara H; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Okuno K; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Nara F; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Matschiner G; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Hashimoto R; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Takahashi T; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
  • Nishizawa T; End-Organ Disease Laboratories (Y.M., Y.N., T.N.), Venture Science Laboratories (S.Y.), Modality Research Laboratories (C.S., T.A., R.M., R.H., T.T.), Drug Metabolism & Pharmacokinetics Research Laboratories (E.S., N.Y.), Biologics Technology Research Laboratories (K.N., H.I., K.O.), and Biologi
J Pharmacol Exp Ther ; 365(2): 368-378, 2018 05.
Article en En | MEDLINE | ID: mdl-29463608
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Recombinantes de Fusión / Albúminas / Lipocalinas / Proproteína Convertasa 9 Límite: Animals / Humans / Male Idioma: En Revista: J Pharmacol Exp Ther Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Recombinantes de Fusión / Albúminas / Lipocalinas / Proproteína Convertasa 9 Límite: Animals / Humans / Male Idioma: En Revista: J Pharmacol Exp Ther Año: 2018 Tipo del documento: Article